Bladder Preservation Therapy for MIBC Predicts Worse Survival

Share this content:
Bladder preservation therapy is associated with decreased overall survival among patients with muscle-invasive bladder cancer.
Bladder preservation therapy is associated with decreased overall survival among patients with muscle-invasive bladder cancer.

SAN DIEGO—Bladder preservation therapy is associated with decreased overall survival compared with radical cystectomy among patients with muscle-invasive bladder cancer (MIBC), according to study findings presented at the American Urological Association 2016 annual meeting.

Using the National Cancer Data Base, investigators at Fox Chase Cancer Center in Philadelphia identified 54,518 patients diagnosed with analytic stage II–III urothelial carcinoma of the bladder from 2003 to 2011. Of these, 27,843 patients underwent radical cystectomy (RC) or received bladder preservation therapy (BPT): 19,745 RC (70.9%) and 8,098 BPT (29.1%).

The researchers stratified the BPT patients into 3 cohorts based on increasingly stringent definitions: any external beam radiotherapy (EBRT, 58.1%), definitive radiotherapy (RT) of 50–80 Gy (26.9%), and definitive RT plus chemotherapy administered within a 3-month time frame (15%). BPT patients typically were older, had worse Charlson comorbidity indices, and were not treated at academic centers, he noted.

In adjusted analyses, RC was associated with improved overall survival compared with BPT, but use of increasingly stringent definitions of BPT attenuated the observed the difference in overall survival, said David Cahn, MD, who reported the study findings. EBRT, definitive RT, and definitive RT plus chemotherapy were associated with a 2.2-fold, 1.9-fold, and 1.56 fold increased risk of death compared with RC, he said.

RELATED: Cytoreductive Cystectomy Aids Survival of Bladder Cancer Patients

Results shows a statistically significant increase in optimal bladder preservation—maximal transurethral resection followed by concurrent radiotherapy and chemotherapy—during the study period, but given the large sample size, the absolute increase was only about 2.4%, Dr. Cahn said.

“These findings and trends may be due to inferior cancer control, measured or unmeasured confounding selection biases, or a combination of both factors,” Dr. Cahn told attendees.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters